ERBB2 and breast cancer: We observed that eIF4E phosphorylation at S209 is a consistent feature in advanced breast cancer patients and in all tested breast cancer cell lines, including an ERα-positive line and HER2-, ERα- and PR-negative lines, which affects the response to chemotherapy (Figures 1 and 3).